Do analysts prefer VBIO or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend RBOT or VERO?

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 3,788.89%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, research analysts plainly believe Vicarious Surgical is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LYRA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or SSKN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 07/10/2026

Compare

VERO vs. VBIO, BJDX, RBOT, LYRA, and SSKN

Should you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include Valion Bio, Inc. Common Stock (VBIO), Bluejay Diagnostics (BJDX), Vicarious Surgical (RBOT), Lyra Therapeutics (LYRA), and Strata Skin Sciences (SSKN). These companies are all part of the "medical equipment" industry.

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valion Bio, Inc. Common Stock has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Venus Concept. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	2.09	-$8.88M	-$6.68	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Venus Concept	-92.76%	-1,904.25%	-85.22%

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Venus Concept. Valion Bio, Inc. Common Stock's average media sentiment score of 1.44 beat Venus Concept's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Positive
Venus Concept	Neutral

Summary

Valion Bio, Inc. Common Stock beats Venus Concept on 9 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Bluejay Diagnostics?

Venus Concept (NASDAQ:VERO) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Bluejay Diagnostics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bluejay Diagnostics' return on equity of -144.27% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

In the previous week, Bluejay Diagnostics had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 0 mentions for Venus Concept. Bluejay Diagnostics' average media sentiment score of 0.29 beat Venus Concept's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Venus Concept	Neutral
Bluejay Diagnostics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bluejay Diagnostics has lower revenue, but higher earnings than Venus Concept. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Summary

Bluejay Diagnostics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Vicarious Surgical?

Vicarious Surgical (NYSE:RBOT) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Venus Concept has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Vicarious Surgical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Vicarious Surgical's return on equity of -184.13% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Venus Concept	-92.76%	-1,904.25%	-85.22%

In the previous week, Vicarious Surgical's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Venus Concept	Neutral

Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 3,788.89%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, research analysts plainly believe Vicarious Surgical is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 11.1% of Vicarious Surgical shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vicarious Surgical and Venus Concept tied by winning 6 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Lyra Therapeutics?

Lyra Therapeutics (NASDAQ:LYRA) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Lyra Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Venus Concept	Neutral

Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.60	-$93.43M	-$19.15	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lyra Therapeutics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Strata Skin Sciences?

Venus Concept (NASDAQ:VERO) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Strata Skin Sciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 40.9% of Strata Skin Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Strata Skin Sciences'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Strata Skin Sciences	Neutral

Strata Skin Sciences has a net margin of -35.64% compared to Venus Concept's net margin of -92.76%. Strata Skin Sciences' return on equity of -476.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Strata Skin Sciences	-35.64%	-476.73%	-33.49%

Strata Skin Sciences has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Strata Skin Sciences	$30.98M	0.00	-$10.09M	-$1.41	N/A

Summary

Strata Skin Sciences beats Venus Concept on 8 of the 11 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$442K	$7.65B	$7.09B	$12.66B
Dividend Yield	N/A	1.32%	2.68%	8.00%
P/E Ratio	-0.01	50.43	27.42	24.53
Price / Sales	0.01	46.09	528.33	96.17
Price / Cash	N/A	26.54	48.47	60.03
Price / Book	0.07	7.44	10.88	6.38
Net Income	-$47M	$159.19M	$3.59B	$331.87M
7 Day Performance	N/A	-0.26%	-0.26%	0.37%
1 Month Performance	N/A	0.27%	4.55%	0.59%
1 Year Performance	-88.15%	4.73%	29.86%	22.26%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.0888 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
VBIO Valion Bio, Inc. Common Stock	1.7051 of 5 stars	$0.51 +0.8%	N/A	-87.5%	$1.63M	$780K	N/A	10	Positive News Short Interest Decrease
BJDX Bluejay Diagnostics	0.2087 of 5 stars	$1.45 +25.0%	N/A	-77.2%	$1.20M	N/A	N/A	9	Short Interest Increase Gap Up High Trading Volume
RBOT Vicarious Surgical	1.5627 of 5 stars	$0.16 -7.2%	$7.00 +4,336.0%	-97.8%	$1.12M	N/A	N/A	210	Gap Up
LYRA Lyra Therapeutics	N/A	$0.60 -15.4%	N/A	-93.8%	$1.07M	$600K	N/A	50	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. VBIO, BJDX, RBOT, LYRA, and SSKN

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Summary

How does Venus Concept compare to Vicarious Surgical?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. VBIO, BJDX, RBOT, LYRA, and SSKN

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Do institutionals and insiders have more ownership in VBIO or VERO?

Which has more volatility and risk, VBIO or VERO?

Which has better earnings and valuation, VBIO or VERO?

Do analysts prefer VBIO or VERO?

Is VBIO or VERO more profitable?

Does the media refer more to VBIO or VERO?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Which has more volatility & risk, VERO or BJDX?

Is VERO or BJDX more profitable?

Does the media favor VERO or BJDX?

Do analysts recommend VERO or BJDX?

Do insiders and institutionals hold more shares of VERO or BJDX?

Which has better valuation and earnings, VERO or BJDX?

Summary

How does Venus Concept compare to Vicarious Surgical?

Which has stronger valuation & earnings, RBOT or VERO?

Is RBOT or VERO more profitable?

Does the media refer more to RBOT or VERO?

Which has more risk and volatility, RBOT or VERO?

Do analysts recommend RBOT or VERO?

Do institutionals & insiders hold more shares of RBOT or VERO?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Which has more volatility & risk, LYRA or VERO?

Does the media refer more to LYRA or VERO?

Is LYRA or VERO more profitable?

Which has better earnings & valuation, LYRA or VERO?

Do analysts rate LYRA or VERO?

Do institutionals and insiders hold more shares of LYRA or VERO?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Which has more risk & volatility, VERO or SSKN?

Do insiders and institutionals believe in VERO or SSKN?

Do analysts recommend VERO or SSKN?

Does the media prefer VERO or SSKN?

Is VERO or SSKN more profitable?

Which has preferable valuation and earnings, VERO or SSKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools